Yr Athro Alan Parker

2021

• Othman, M.et al. 2021. To clot or not to clot? Ad is the question - insights on mechanisms related to vaccine induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis 19(11), pp. 2845-2856. (10.1111/jth.15485)
• Nestic, D.et al. 2021. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13(10), article number: 1585. (10.3390/pharmaceutics13101585)
• Teijeira Crespo, A.et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163(4), pp. 389-398. (10.1111/imm.13323)
• Bates, E. A.et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
• Davies, J. A.et al. 2021. Efficient intravenous tumor targeting using the αvβ6 integrin-selective precision virotherapy Ad5NULL-A20. Viruses 13(5), article number: 864. (10.3390/v13050864)
• Baker, A. T.et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)

2020

• Wongthida, P.et al. 2020. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology 22(12), pp. 1757-1770. (10.1093/neuonc/noaa126)
• Hulin-Curtis, S.et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
• Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
• Mowbray, N. G.et al. 2020. Safe management of surgical smoke in the age of COVID-19. British Journal of Surgery 107(11), pp. 1406-1413. (10.1002/bjs.11679)
• Scurr, M. J.et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
• Crowther, M. D.et al. 2020. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology 21, pp. 178 - 185. (10.1038/s41590-019-0578-8)

2019

• Man, S.et al. 2019. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports 9, article number: 12840. (10.1038/s41598-019-49150-9)
• Baker, A.et al. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5(9), article number: eaax3567. (10.1126/sciadv.aax3567)
• Baker, A. T.et al. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. bioRxiv (10.1101/580076)
• Baker, A. T.et al. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications 10, article number: 741. (10.1038/s41467-019-08599-y)

2018

• Uusi-Kerttula, H.et al. 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24(17), pp. 4215-4224. (10.1158/1078-0432.CCR-18-1089)
• Baker, A.et al. 2018. Designer oncolytic adenovirus: coming of age. Cancers 10(6), article number: 201. (10.3390/cancers10060201)
• Hulin-Curtis, S.et al. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9(41), pp. 26328-26341. (10.18632/oncotarget.25242)
• Man, Y. K. S.et al. 2018. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics 17(2), pp. 575-587. (10.1158/1535-7163.MCT-17-0671)
• Uusi-Kerttula, H. and Parker, A. L. 2018. Precision virotherapies: Coming soon. Oncotarget 9(86) (10.18632/oncotarget.26280)

2017

• Yan, B.et al. 2017. Superlensing microscope objective lens. Applied Optics 56(11), pp. 3142-3147. (10.1364/AO.56.003142)

2016

• Robertson, S.et al. 2016. Retargeting FX binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. Journal of General Virology 97(8), pp. 1911-1916. (10.1099/jgv.0.000505)
• Hulin-Curtis, S.et al. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22)
• Uusi-Kerttula, H.et al. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545)

2015

• Uusi-Kerttula, H.et al. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7(11), pp. 6009-6042. (10.3390/v7112923)
• Uusi-Kerttula, H.et al. 2015. Incorporation of avß6 integrin-targeting peptide into chimaeric Ad5/fibre knob 48 vector results in efficient tumour-targeting and evasion of neutralisation in clinical ascites. Human Gene Therapy 26(10), pp. A93-A93., article number: P224. (10.1089/hum.2015.29008.abstracts)
• Uusi-Kerttula, H.et al. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to αvβ6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites. Human Gene Therapy 26(9), pp. A33-A33., article number: PO71. (10.1089/hum.2015.29005.abstracts)
• Uusi-Kerttula, H.et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites. Human Gene Therapy 26(9), pp. A23-A23., article number: PO39. (10.1089/hum.2015.29005.abstracts)
• Hulin-Curtis, S.et al. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34., article number: PO72. (10.1089/hum.2015.29005.abstracts)
• Uusi-Kerttula, H.et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26(5), pp. 320-329. (10.1089/hum.2015.015)
• Dakin, R. S.et al. 2015. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy 26(5), pp. 312-319. (10.1089/hum.2015.019)
• Nivsarkar, M. S.et al. 2015. Evidence for contribution of CD4+CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery. Journal of Immunology Research 2015, article number: 397879. (10.1155/2015/397879)

2014

• Guinn, B.et al. 2014. 8th international conference on oncolytic virus therapeutics. Human Gene Therapy 25(12), pp. 1062-1084. (10.1089/hum.2014.118)
• Dakin, R. S.et al. 2014. Efficient gene transfer to human vascular cells in vitro and ex vivo using adenovirus serotype 49. Cardiovascular Research 103(suppl), pp. S42. (10.1093/cvr/cvu082.170)
• Coughlan, L.et al. 2014. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy 25(4), pp. 385-394. (10.1089/hum.2014.016)

2013

• Parker, A. L.et al. 2013. Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. eds. Adenovirus., Vol. 1089. Methods in Molecular Biology Humana Press, pp. 45-59., (10.1007/978-1-62703-679-5_3)
• Parker, A. L.et al. 2013. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy 20(12), pp. 1158-1164. (10.1038/gt.2013.44)
• White, K. M.et al. 2013. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery 8(1), article number: 183. (10.1186/1749-8090-8-183)
• Kaur, H.et al. 2013. Fucoidan improves adenovirus mediated thrombocytopenia and enhances viral liver transduction [Abstract]. Journal of Thrombosis and Haemostatis 11(S1), pp. 451-452. (10.1111/jth.12284)
• Duffy, M. R.et al. 2013. Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release 170(1), pp. 132-140. (10.1016/j.jconrel.2013.05.007)

2012

• Coughlan, L.et al. 2012. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy 20(12), pp. 2268-2281. (10.1038/mt.2012.162)
• Duffy, M. R.et al. 2012. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine 7(2), pp. 271-288. (10.2217/nnm.11.186)

2011

• Coughlan, L.et al. 2011. In vitro assessment of targeting peptide incorporation within the knob domain of human adenovirus type 48 fiber. Human Gene Therapy 22(10), pp. A128-A128.
• Duffy, M. R.et al. 2011. A Cluster of Basic Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of Adenovirus/FX Complexes. Journal of Virology 85(20), pp. 10914-10919. (10.1128/JVI.05382-11)
• Duffy, M. R.et al. 2011. A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus:FX complexes [Abstract]. Human Gene Therapy 22(10), pp. A34-A34. (10.1089/hum.2011.2525)
• Kitahara, H.et al. 2011. COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78. Molecular Cancer Research 9(6), pp. 688-701. (10.1158/1541-7786.MCR-10-0470)

2010

• Othman, M.et al. 2010. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 116(18), pp. 3645-3652. (10.1182/blood-2009-12-261131)
• Alba, R.et al. 2010. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116(15), pp. 2656-2664. (10.1182/blood-2009-12-260026)
• Bradshaw, A. C.et al. 2010. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. Plos Pathogens 6(10), article number: e1001142. (10.1371/journal.ppat.1001142)
• Coughlan, L.et al. 2010. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2(10), pp. 2290-2355. (10.3390/v2102290)
• Duffy, M. R.et al. 2010. Modification of the factor X serine protease domain ablates heparan sulfate proteoglycan engagement by Ad5-FX complexes. Human Gene Therapy 21(9), pp. 1187-1187. (10.1089/hum.2010.804)
• Collins, L.et al. 2010. Self-assembly of peptides into spherical nanoparticles for delivery of hydrophilic moieties to the cytosol. ACS Nano 4(5), pp. 2856-2864. (10.1021/nn901414q)
• Parker, A. L.et al. 2010. In vitro evaluation of hexon modifications on the capacity of Ad5 to evade neutralising antibodies. Human Gene Therapy 21(4), pp. 518-518. (10.1089/hum.2010.1225)
• Duffy, M. R.et al. 2010. Modification of the FX serine protease domain ablates HSGP engagment by Ad5/FX complexes. Human Gene Therapy 21(4), pp. 512-513. (10.1089/hum.2010.1225)
• Alba, R.et al. 2010. Biodistribution and inflammatory profiles of hepatocyte-detargeted FX-binding ablated Ad5 vectors. Human Gene Therapy 21(4), pp. 498-499. (10.1089/hum.2010.1224)

2009

• Greig, J. A.et al. 2009. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Molecular Therapy 17(10), pp. 1683-1691. (10.1038/mt.2009.152)
• Alba, R.et al. 2009. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114(5), pp. 965-971. (10.1182/blood-2009-03-208835)
• Greig, J. A.et al. 2009. Influence of factor X on in vitro and in vivo gene delivery by Ad5 and Ad35 vectors. Molecular Therapy 17, pp. S325-S325.
• Parker, A. L.et al. 2009. Genome wide and micro RNA profiling of murine livers following acute phase intravenous delivery of Ad5 reveals subsets of hepatocyte and kupffer cell regulated genes. Molecular Therapy 17, pp. S43-S44.
• Alba, R.et al. 2009. Selected modification of the adenovirus type 5 hexon modulates interaction with coagulation factor X and hepatocyte transduction in vivo. Molecular Therapy 17, pp. S6-S6.
• Parker, A.et al. 2009. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. Journal of Virology 83(1), pp. 479-483. (10.1128/JVI.01878-08)

2008

• Parker, A., Nicklin, S. A. and Baker, A. H. 2008. Interactions of adenovirus vectors with blood: Implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics 10(5), pp. 439-448.
• Waddington, S. N.et al. 2008. A critical role for the adenovirus serotype 5 hexon in liver gene transfer. Human Gene Therapy 19(4), pp. 409-409. (10.1089/hum.2008.1327)
• Parker, A.et al. 2008. An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy 19(4), pp. 407-407. (10.1089/hum.2008.1327)
• Greig, J. A.et al. 2008. Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35. Human Gene Therapy 19(4), pp. 398-398.
• Waddington, S. N.et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132(3), pp. 397-409. (10.1016/j.cell.2008.01.016)
• Kubo, N.et al. 2008. Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. Journal of Drug Targeting 16(5), pp. 396-404. (10.1080/10611860802088796)

2007

• Waddington, S. N.et al. 2007. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology 81(17), pp. 9568-9571. (10.1128/JVI.00663-07)
• Parker, A. L.et al. 2007. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1770(9), pp. 1331-1337. (10.1016/j.bbagen.2007.06.009)
• Parker, A. L.et al. 2007. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology 81(7), pp. 3627-3631. (10.1128/JVI.02786-06)
• Maruta, F.et al. 2007. Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of Drug Targeting 15(4), pp. 311-319. (10.1080/10611860701195510)

2006

• Akita, N.et al. 2006. Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Science 97(10), pp. 1075-1081. (10.1111/j.1349-7006.2006.00291.x)
• Parker, A. L.et al. 2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108(8), pp. 2554-2561. (10.1182/blood-2006-04-008532)
• Parker, A. L.et al. 2006. Hepatic tropism of adenoviral type 5 vectors can be mediated by multiple coagulation factors. Molecular Therapy 13(S1), pp. S143-S143. (10.1016/j.ymthe.2006.08.436)
• Shimizu, A.et al. 2006. Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology 71(1-2), pp. 136-145. (10.1159/000100479)

2005

• Parker, A. L.et al. 2005. Exploration of peptide motifs for potent non-viral gene delivery highly selective for dividing cells. Journal of Gene Medicine 7(12), pp. 1545-1554. (10.1002/jgm.809)
• Read, M. L.et al. 2005. 12th Annual Congress of the European Society of Gene Therapy. Expert Opinion on Biological Therapy 5(1), pp. 137-141. (10.1517/14712598.5.1.137)
• Parker, A. L.et al. 2005. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting 13(1), pp. 39-51. (10.1080/10611860400020449)

2004

• Parker, A. L.et al. 2004. Free and (Lys)(16) containing fusogenic peptides for non-viral gene delivery to dividing and post mitotic cells. Journal of Gene Medicine 6(9), pp. S13-S13.
• Parker, A. L.et al. 2004. Nonviral gene delivery: techniques and implications for molecular medicine. Expert Reviews in Molecular Medicine 5, pp. 1-15. (10.1017/S1462399403006562)

2003

• Maruta, F.et al. 2003. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. Journal of Drug Targeting 11(1), pp. 53-59.

2002

• Parker, A. L. and Seymour, L. W. 2002. Targeting of polyelectrolyte RNA complexes to cell surface integrins as an efficient cytoplasmic transfection mechanism. Journal of Bioactive and Compatible Polymers 17(4), pp. 229-238. (10.1106/088391102027977)
• Maruta, F.et al. 2002. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Therapy 9(6), pp. 543-552. (10.1038/sj.cgt.7700470)
• Parker, A. L.et al. 2002. Methodologies for monitoring, nanoparticle formation by self-assembly of DNA with poly(L-lysine). Analytical Biochemistry 302(1), pp. 75-80. (10.1006/abio.2001.5507)
• Oupicky, D., Parker, A. L. and Seymour, L. W. 2002. Laterally stabilized complexes of DNA with linear reducible polycations: Strategy for triggered intracellular activation of DNA delivery vectors. Journal of the American Chemical Society 124(1), pp. 8-9. (10.1021/ja016440n)

2000

• Carlisle, R. C.et al. 2000. Systems for gene delivery based on combination of viral and non-viral vectors. Targeting of Drugs 323, pp. 117-125.